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significance of this study
What is already known on this topic
 ► Occult inflammation in patients with 
inflammatory bowel disease (IBD) is 
associated with a higher risk of adverse 
disease course.
 ► In Crohn’s disease clinical trials treat to 
target approaches have been associated 
with better clinical outcomes.
 ► Treatment adherence in IBD is often poor.
What this study adds
 ► Patient views on treat to target: 66% 
agree with this approach.
 ► One- third of patients remains unconvinced 
of a treat to target approach.
 ► There is an unmet need for patient on 
education on treat to target approaches.
How might it impact on clinical 
practice in the foreseeable future?
 ► Clinicians will need to consider how to 
provide sufficient patient education to 
explain the rationale and concept of treat 
to target approaches.
AbstrAct
Background A ‘treat to target’ approach aiming 
for remission of clinical symptoms and absence 
of mucosal inflammation has been proposed in 
inflammatory bowel disease (IBD). We aimed to 
establish whether patients with IBD in clinical 
remission find this approach acceptable.
Methods Patients in glucocorticosteroid- free 
clinical remission underwent a face- to- face 
structured, quantitative interview and rated the 
acceptability of treat to target on a 10- point 
Likert scale. We analysed factors associated with 
agreement to treat to target.
Results The cohort comprised 298 patients (144 
Crohn’s disease, 136 ulcerative colitis, 18 IBD- 
unclassified). Elevated C- reactive protein was 
found in 24.4% and elevated faecal calprotectin 
in 17.7%. Overall, 66.2% of patients rated a 
treat to target approach as acceptable (Likert 
scale ≥8). Acceptable treatment aims for 
patients were avoidance of flare, hospitalisation, 
surgery and colorectal cancer. Using binary 
logistic regression analysis the following were 
not predictive of accepting a treat to target 
approach: age, diagnosis, disease phenotype, 
surgical history, disease duration, patient 
knowledge, adherence, anxiety, depression 
and patient- reported control of disease. Better 
adherence to current therapy was associated 
with accepting a treat to target approach 
(B=0.16, p=0.039).
Conclusion In a cohort of patients in clinical 
remission, where this strategy is most relevant, 
two- thirds of patients agreed with treat to 
target. Patients with better current adherence 
were more likely to accept treat to target. 
Patient education and counselling materials will 
need to be developed to convince a substantial 
minority of patients of the importance of treat 
to target.
IntroductIon
Medical treatment for inflammatory 
bowel disease (IBD) has undergone a 
complete transformation over the last 25 
years, due to the advent of newer biolog-
ical and novel small molecule treatments.1 
Patients benefit from anti- tumour necrosis 
factor (anti- TNF) agents, anti- integrin 
and anti- interleukin 12/23 (IL-12/23) 
drugs and the first small molecule has 
recently become available, with more in 
development.2–5 Traditional treatment 
approaches were based on a step- up prin-
ciple involving mesalazine (for ulcerative 
colitis (UC) only), to immunomodulators 
and then biological agents.6 However, this 
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approach can lead to long delays in achieving remis-
sion, and subsequent poor quality of life or even devel-
opment of IBD- related complications and surgery.
Traditionally the mainstay of therapy was to achieve 
clinical remission, or absence of symptoms, ideally in 
a glucocorticosteroid- free setting. This target is easily 
understood by patients, and glucocorticosteroid- free 
clinical remission is one of the main patient goals.7 
However, a substantial proportion of patients in clin-
ical remission have evidence of ongoing inflamma-
tion.8 Patients with such ‘occult’ inflammation may be 
at a higher risk of developing disease- related compli-
cations, including flares, hospitalisation and the need 
for surgery, while those achieving mucosal healing 
are at a much- reduced risk of complications.9–14 
Recently, different treatment approaches have been 
proposed. These include a top- down approaches for 
Crohn’s disease (CD) using combination therapy of 
immunomodulator and anti- TNF early in the disease 
course to avoid long- term complications.15 In addition 
approaches aiming for a more stringent target than 
clinical remission have been proposed. The Selecting 
Therapeutic Targets in IBD (STRIDE) consensus has 
defined mucosal healing targets for both UC and 
CD.16 Although mucosal healing is yet to become a 
universally agreed target for clinical care. A ‘treat to 
target’ approach where, instead of aiming for clinical 
remission, a treatment target such as mucosal healing 
is agreed with the patient has been proposed as a new 
standard of care.16 17 Regular disease assessment would 
then occur to ensure therapy is escalated until clinical 
remission and mucosal healing is achieved. Two clin-
ical trials have shown that a treat to target approach 
leads to better medium- term outcomes in CD.11 18
A recent systematic review has examined the 
evidence for a treat to target approach in UC.17 This 
has highlighted that questions regarding the best treat-
ment targets incorporating clinical, endoscopic, histo-
logical and non- invasive measure of inflammation 
and how to measure them, remain.17 The review also 
confirmed that there are gaps in the current evidence 
base to justify widespread implementation of treat to 
target approaches. Importantly, it also underlined the 
importance of incorporating the patient’s perspective 
into these new approaches.17 However, treatment in 
IBD is complicated by high rates of non- adherence to 
IBD- related medications by patients.19 20 In light of 
the uncertainty surrounding the patient perspective 
of treat to target, we aimed to establish whether this 
approach is, in principle, acceptable to those in whom 
this strategy is most relevant; patients with IBD who 
are in clinical remission.
Methods
Population and setting
Leeds Teaching Hospitals NHS Trust provides 
secondary and tertiary care to approximately 3000 
patients with IBD in dedicated clinics provided by 
gastroenterologists with a subspecialty interest in IBD. 
The study population includes an unselected cohort of 
all patients with IBD in the hospital catchment area. In 
accordance with current guidance from the National 
Institute of Health and Care Excellence, choice of 
therapy is largely based on the aim of achieving 
glucocorticosteroid- free clinical remission.4 At the 
time this study was conducted, this patient cohort 
was therefore naïve to the concept of treat to target. 
Furthermore, the concept of treat to target was not 
previously discussed with patients under the Leeds 
IBD service. For the purpose of this study we defined 
the concept of treat to target as aiming for the absence 
of mucosal inflammation.
recruitment
Consecutive patients identified as having achieved clin-
ical remission, as assessed by physician global assess-
ment, were identified. After written informed consent 
was obtained, participants underwent a 30- min face- to- 
face quantitative interview with a single research nurse 
using an interviewer administered questionnaire, the 
details of which are outlined below. The study nurse 
introduced the hypothetical study scenario that a stool 
test, blood test, imaging or an endoscopy had showed 
abnormal levels of inflammation. The study nurse then 
explained to the patient that this means a higher risk of 
disease progression (including flares, hospitalisation, 
surgery or the risk of developing colorectal cancer), 
to the patient. For this verbal explanations were used 
but not visual or written materials were offered to the 
participant. The patient was then instructed to base 
all responses on this scenario. It was made clear that 
this was a hypothetical research exercise, rather than 
a conversation based on the results of an individual 
patient’s tests. We did not propose any specific treat-
ments to the patient but assessed their general attitude 
towards the treat to target concept.
Inclusion criteria
All adults aged 18 years and over with a confirmed 
diagnosis of IBD, who were judged to be in clinical 
glucocorticosteroid- free remission by global physi-
cian assessment were eligible for the study. Patients 
did not have to be taking maintenance therapy for 
their IBD to be eligible for inclusion. Study eligibility 
included patients with normal or elevated inflamma-
tion markers, normal imaging or radiological evidence 
of active disease and normal endoscopic investigations 
or endoscopic evidence of active disease. Patients were 
not required to have undergone any recent imaging or 
endoscopy as part of the study.
exclusion criteria
Patients who lacked the capacity to consent and patients 
unable to communicate in English were excluded. 
Those patients with a current acute flare of their IBD or 
symptoms attributed to ongoing disease activity were 
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also excluded from participation. Glucocorticosteroid 
use, including budesonide, was not permitted within 2 
weeks prior to recruitment. Patients with UC, who had 
a colectomy, were not eligible for participation.
data collection
Data regarding the medical, social and disease- specific 
history (demographics, diagnosis and phenotype, 
previous surgery, previous hospitalisations and latest 
blood, stool, radiology or endoscopy results) were 
collected from the hospital electronic and paper 
records. Medication history was recorded from the 
electronic hospital records. As the study recruited 
from 2015 to early 2017 anti- IL-12/23 therapy was 
not locally available for most of the study period and 
use of anti- integrins was infrequent during the study 
period and therefore not captured. Participants were 
asked to provide a stool sample at baseline for faecal 
calprotectin (FC) measurement. FC was deemed 
elevated at readings ≥250 µg/g and C- reactive protein 
(CRP) was deemed elevated at readings ≥5 mg/L.
Questionnaires
We used five questionnaires and, where available, fully 
validated instruments were used. All participants were 
judged to be in clinical remission by the responsible 
physician, but to ascertain patients’ perceptions all 
participants were asked to report their perception of 
the state of their IBD using a 10- point Likert scales 
(1—very poor to 10—excellent) separately for current 
disease state and disease state over the last 3 years. We 
used the Hospital Anxiety and Depression Scale (HADS) 
to assess for anxiety and depression,21 the Short IBD 
Quality of Life Questionnaire to assess quality of life22 
and the Medication Adherence Report Scale (MARS) 
to assess adherence to current maintenance medica-
tion.23 24 Disease- related patient knowledge was meas-
ured with the short IBD knowledge questionnaire.25 
Patients were asked to rate how acceptable a treat to 
target approach was to them on 10- point Likert scales. 
In accordance with adherence studies (cut- off usually 
80%) we determined that a Likert scale rating of ≥8 
represented acceptance of a treat to target approach.26 
We also asked patients about their views on specific 
therapeutic goals. Participants were asked whether 
avoiding complications including a disease flare during 
the next year, an IBD- related hospitalisation during 
the next year, the need for surgery during the next 5 
years or the development of colorectal cancer during 
the next 20 years were desirable treatment goals. For 
each goal we asked participants what level of risk of 
the complication occurring (10%–100%, presented 
as a 10- point Likert scale) would be required in order 
for them to deem this an acceptable treatment goal. 
Participants were then asked what level of benefit they 
would expect from medical therapy in order to avoid 
the disease complication (presented as a relative risk 
reduction (RRR) 10%, 25%, 50%, 90%).
Primary outcome
The primary outcome was defined as the percentage of 
patients accepting treat to target, defined by a Likert 
scale score of ≥8.
secondary outcomes
Secondary outcomes included factors influencing the 
choice for or against a treat to target approach, and an 
assessment of treatment goals for patients, including 
the level of risk of an adverse event occurring that 
would be required to accept treatment, as well as the 
level of benefit expected by patients.
sample size and recruitment plan
As no estimates for the primary outcome existed, no 
formal power calculation was performed. The study 
target was 300–400 patients, representing 10% of 
the IBD clinic cohort, which was deemed sufficient to 
gain data that were representative of the entire clinic 
cohort.
statistical analysis plan
Data analysis was performed using SPSS V.25.0. Patient 
demographics, IBD phenotype and treatment history 
were reported using descriptive statistics. Continuous 
variables were compared using an independent t- test 
for normally distributed data and a Mann- Whitney 
U test for non- normally distributed data. Categorical 
variables were analysed using Pearson χ2 test. Asso-
ciations were tested using Spearman correlation. We 
considered all analysis yielding p values <0.05 to be 
statistically significant. To assess for independence 
of factors, categorical factors were analysed again as 
dichotomous variables (for medication ever vs never 
exposure; for disease type UC vs CD). All factors were 
entered into a binary logistic regression analysis model 
(using treat to target acceptance as the selection vari-
able and all variates from table 3 as the covariates with 
enter method of analysis) to assess for independent 
factors associated with accepting a treat to target 
approach.
results
Patient characteristics
The cohort comprised 298 patients (145 males; 48.9%) 
including 144 with CD (48.3%), 136 with UC (45.6%) 
and 18 with IBD- unclassified (IBD- U) (6.1%). Median 
age was 46 years, and median disease duration 7 years 
(table 1). Current medications included mesalazine in 
44.3%, thiopurines in 30.5%, biologicals in 26.1% 
and methotrexate in 3.2%. 96 patients (32.2%) had 
never been exposed to immunosuppressive treatment. 
Abnormal HADS anxiety scores (defined as ≥11) were 
present in 22.5% and abnormal depression scores in 
11.4% (table 2). Non- adherence, defined as MARS 
≤16, occurred in 15.8%, and the median knowledge 
score was 3.
H
ospital M
edical Library. Protected by copyright.
 o
n
 M
arch 11, 2020 at Assistant Librarian St Jam
es`s
http://fg.bmj.com/
Frontline G
astroenterol: first published as 10.1136/flgastro-2019-101366 on 24 January 2020. Downloaded from
 
Selinger C, et al. Frontline Gastroenterology 2020;0:1–9. doi:10.1136/flgastro-2019-1013664
COlOreCtAl
Figure 1 Percentage of patients rating the acceptability of treat 
to target on a 10- point Likert scale. A score of 1 indicates the lowest 
acceptability of treat to target whereas a score of 10 indicates 
the highest acceptability of treat to target. A score of 8 or greater 
represents acceptance of treat to target.
Table 1 Cohort composition
n Percentage
Sex
  Male 145 48.70
  Female 153 51.30
Median age 46 years
Median disease duration 7 years
Diagnosis
  CD 144 48.30
  UC 136 45.60
  IBD- U 18 6
UC/IBD- U extent
  E1 (proctitis) 22 14.40
  E2 (left- sided colitis) 82 53.60
  E3 (extensive colitis) 49 32.00
  Unknown 1
CD phenotype
  A1 (<16 years at diagnosis) 6 4.20
  A2 (17–40 years) 108 75.00
  A3 (>40 years) 30 20.80
  L1 (ileal) 47 32.90
  L2 (colonic) 37 25.90
  L3 (ileo- colonic) 59 41.20
  L4 (upper GI, isolated and/or modifier) 13 9.00
  L not known 1
  B1 (inflammatory) 69 47.90
  B2 (structuring) 41 28.50
  B3 (penetrating) 34 23.60
  Perianal disease 35 32.10
Previous IBD- related surgery 70 23.50
Mesalazine
  Previous 95 31.90
  Current 132 44.30
Thiopurines
  Previous 97 32.60
  Current 91 30.50
Methotrexate
  Previous 10 3.40
  Current 8 2.70
First anti- TNF
  Previous 45 15.10
  Current 60 20.10
Second anti- TNF
  Previous 7 2.30
  Current 18 6.00
CD, Crohn’s disease; IBD, inflammatory bowel disease; TNF, tumour 
necrosis factor; UC, ulcerative colitis.
Table 2 Psychometric results and current medical state
n Percentage
HADS
  No anxiety (score 0–7) 140 47.00
  Mild anxiety (score 8–10) 91 30.50
  Definite abnormal anxiety (score ≥11) 67 22.50
  No anxiety (score 0–7) 192 64.40
  Mild depression (score ≥8) 72 24.20
  Definite abnormal depression (score ≥11) 34 11.40
Medication adherence (MARS)
  Adherent (score >16) 251 84.20
  Non- adherent (score ≤16) 47 15.80
Inflammation status
  Abnormal CRP (>5 mg/L) 73 24.40
  Abnormal FC (≥250 µg/g) 53 17.70
CRP, C- reactive protein; FC, faecal calprotectin; HADS, Hospital Anxiety 
and Depression Scale; MARS, Medication Adherence Report Scale.
symptoms and objective inflammation
Patients self- rated their current symptomatic state 
(control) and the state (control) over the last 3 years 
of their IBD on 10- point Likert scales (0 poor control, 
10 excellent control). Subjectively, very good current 
control (≥8) was reported by 60.9% and very good 
control (≥8) over the last 3 years by 31.2%. An 
elevated CRP was found in 24.4%, and an elevated 
FC in 17.7%. Patient- reported current control of IBD 
correlated only weakly with FC (Pearson −0.169; 
p=0.004), but not with CRP (Pearson −0.075; p=0.2). 
No correlation between CRP or FC and control over 
the last 3 years was found.
treat to target acceptance and associated factors
Overall, 66.2% of patients rated a treat to target 
approach as acceptable (figure 1). We performed 
a sensitivity analysis on the primary outcome. By 
lowering the threshold for acceptance to ≥7 73% 
would have been classed as accepting treat to target 
while increasing the threshold to ≥9 would have 
classed 57.8% as accepting. There was no association 
between age, diagnosis, disease phenotype, surgical 
history, disease duration, patient knowledge, anxiety, 
depression or patient- reported state of disease, either 
current or over the last 3 years and acceptance of a treat 
to target approach (table 3). Patients on a second- line 
H
ospital M
edical Library. Protected by copyright.
 o
n
 M
arch 11, 2020 at Assistant Librarian St Jam
es`s
http://fg.bmj.com/
Frontline G
astroenterol: first published as 10.1136/flgastro-2019-101366 on 24 January 2020. Downloaded from
 
Selinger C, et al. Frontline Gastroenterology 2020;0:1–9. doi:10.1136/flgastro-2019-101366  5
COlOreCtAl
Table 3 Factors associated with accepting treat to target approach
Treat to target
not accepting
Treat to target
accepting Univariate analysis Binary logistic regression
Diagnosis (n)
  CD 54 90 B=−1.28
  UC 38 98
  IBD- U 8 10 p=0.2 p=0.021
IBD- related surgery (n) B=0.95
  Yes 18 52
  No 82 146 p=0.2 p=0.08
Mesalazine treatment (n)
  Never 26 45 B=−0.49
  Previous 34 61
  Current 40 92 p=0.7 p=0.3
Thiopurine treatment (n)
  Never 38 72 B=0.3
  Previous 33 64
  Current 29 62 p=0.9 p=0.5
First- line anti- TNF treatment (n)
  Never 67 126 B=−0.56
  Previous 20 25
  Current 13 47 p=0.08 p=0.3
Second- line anti- TNF treatment (n)
  Never 84 186 B=0.63
  Previous 1 6
  Current 12 6 p=0.012 p=0.4
Disease duration (median in years, not 
normally distributed)
7 8 p=0.4 B=−0.004
p=0.9
Age (mean in years, normally distributed) 44.7 48.7 p=0.07 B=−0.006
p=0.7
Patient knowledge (mean, normally 
distributed)
4 4 p=0.09 B=0.66
p=0.5
CRP (available for 281 patients, median, 
not normally distributed)
1 1 p=0.7 B=0.59
p=0.1
FC (186 samples returned, median, not 
normally distributed)
104 111 p=0.7 B=0
p=0.4
Patient- reported current disease control 
(10- point Likert scale, median, not 
normally distributed)
9 8 p=0.6 B=0.13
p=0.6
Patient- reported 3- year disease control 
(10- point Likert scale, median, not 
normally distributed)
7 7 p=0.6 B=0.04
p=0.6
HADS anxiety (median, not normally 
distributed)
8 7 p=0.2 B=−0.26
p=0.8
HADS depression (median, not normally 
distributed)
7 6 p=0.4 B=−0.13
p=0.2
Medication adherence (MARS, median, 
not normally distributed)
19 20 p=0.032 B=0.16
p=0.039
Quality of life (SIBDQ, median, not 
normally distributed)
54 56 p=0.4 B=−0.55
p=0.1
CD, Crohn’s disease; FC, faecal calprotectin; HADS, Hospital Anxiety and Depression Scale; IBD, inflammatory bowel disease; MARS, Medication 
Adherence Report Scale; NB, where figures do not add up to 298 the relevant status was not known for some patients; SIBDQ, Short IBD Quality of Life 
Questionnaire; TNF, tumour necrosis factor; UC, ulcerative colitis.
anti- TNF were less likely to agree to a treat to target 
approach (p=0.012). Better self- reported medication 
adherence, as measured by MARS, was associated 
with accepting a treat to target approach (median 20 
vs 19 for not accepting, p=0.023). However, median 
adherence scores in both accepting and non- accepting 
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groups were high (adherence is defined as MARS >16). 
Binary logistic regression analysis revealed that only 
better adherence to medication was independently 
associated with accepting a treat to target approach 
(B=0.16, p=0.039; table 3). We examined predictive 
factors separately for UC and CD: the only positive 
predictor of acceptability in UC was higher knowledge 
(4.03 vs 3.21, p=0.026); while in CD second- line 
anti- TNF use (lower acceptance, p=0.13) and higher 
MARS adherence scores (higher acceptance, p=0.011) 
were associated with acceptance of treat to target.
treatment target acceptance and risk reduction
Patients rated the acceptability of treatment aims, as 
well as the level of absolute risk and the level of benefit 
(RRR) needed to convince them to take on escalation 
of treatment. For the level of absolute risk of a flare 
during the next year needed to convince them to take 
extra treatment: at a 50% risk level 78.7% would accept 
treatment escalation (table 4). A 25% RRR was consid-
ered acceptable for treatment escalation by 43.3%. For 
the level of absolute risk of an IBD- related hospitali-
sation over the next year needed to convince them to 
take extra treatment: at a 50% risk level 79.4% would 
accept treatment escalation. A 25% RRR was consid-
ered acceptable for treatment escalation by 47.8%. For 
the level of absolute risk of IBD- related surgery over 
the next 5 years needed to convince them to take extra 
treatment: at a 50% risk level 80.7% would accept 
treatment. A 25% RRR was considered acceptable for 
treatment escalation by 50.2%. For the level of abso-
lute risk of a colorectal over the next 20 years needed 
to convince them to take extra treatment: at a 50% 
risk level 83.5% would accept treatment escalation. 
A 25% RRR was considered acceptable for treatment 
escalation by 53.5%.
There were no significant differences in the risk and 
benefits levels expected by patients with prior surgery 
compared with those without in respect of avoidance 
of hospitalisation, surgery or colorectal cancer.
dIscussIon
This study examined patient views on a treat to target 
approach. Although medical opinion is shifting away 
from a symptom- based treatment approach to one 
aiming for at least mucosal healing with a treat to target 
strategy,12 16 to date little attention has been paid to the 
patient perspective.17 Our study addresses an impor-
tant gap in current evidence and demonstrates that, 
in a large cohort of patient not previously exposed 
to the concept of treat to target, 66.8% agreed to the 
approach in principle. Conversely, a third of patients 
did not agree with treat to target. This highlights an, 
as yet, unmet need to convince these patients of the 
benefits of treat to target.
Our study examined the views of patients in clin-
ical remission, who are the most relevant, as this is 
the precise group of patients who would face further 
investigations, and possibly treatment escalation, 
under a treat to target approach. While patients with 
active disease face choices over treatments targets as 
well there are distinct differences between the two 
groups. First, patients with active disease are more 
likely adherent to treatment. Second, patients with 
active disease are mainly motivated by wanting to 
achieve symptom control a target already achieved for 
those patients in clinical remission. We chose Physician 
Global Assessment as the criterion for clinical remission 
as very few centres use formal disease activity scores 
such as Harvey- Bradshaw Index or Mayo Score in 
routine clinical encounters. The aim was to reflect real 
life clinical practice in identifying patients in clinical 
remission. To understand better which patients agree 
and which disagree with treat to target we examined 
several potentially associated demographic, disease- 
related, psychological, disease educational and treat-
ment history- related factors. Interestingly, treatment 
with a second- line anti- TNF therapy was associated 
with a lower likelihood of accepting treat to target on 
univariate analysis only. This may relate to a history of 
previous treatment failures, and therefore represents 
patients with difficult to manage IBD. Patients in this 
situation are probably the least likely to benefit from a 
treat to target approach, as the benefits are expected to 
be higher in patients with shorter disease duration, and 
without previous treatment failures.12 Better current 
medication adherence was associated with an increased 
likelihood of accepting a treat to target approach, but 
median adherence levels in both accepting and non- 
accepting patients were high.
Previous studies had examined patient views on 
accepting risk for maintenance of clinical remis-
sion only.27 In that scenario patients were willing to 
accept a 22.8% chance of a serious infection, and a 
1.8% chance of a lymphoma, over a 5- year time 
horizon in order to maintain clinical remission.27 We 
explored patients’ views on different treatment targets 
including avoidance of flare, hospitalisation, surgery 
and colorectal cancer. There were surprisingly similar 
results for all four targets, suggesting that avoidance 
of any disease complication, rather than one compli-
cation in particular, is most relevant to patients. There 
is therefore a large unmet need for specific treat to 
target education for patients, in order to highlight the 
potential benefits of this approach. While two- thirds 
of patients indicated acceptance in our study, we 
cannot assume that this figures translates completely 
into ‘real- world’ acceptance, especially in light of non- 
adherence rates to treatments aimed at symptomatic 
remission of between 30% and 45%.19 Patients seemed 
to be willing to accept significant risks in order to 
maintain disease control in a previous study of willing-
ness to accept medication.27 Interestingly, that study 
found that symptomatic patients were less willing to 
accept risks than those in clinical remission.27 Lessons 
learnt from adherence research and studies reporting 
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Table 4 Patient expectation on treatment targets
Outcome to avoid
Minimum level of risk 
to agree to this target 
(%)
Patient numbers 
(accumulative 
percentage)
Minimum level of risk 
reduction benefit to 
agree to this target 
(%)
Patient numbers 
(accumulative 
percentage)
Flare during next year
  
  
  
  
  
  
  
  
  
10 51 (18.4) 10 53 (19.1)
20 23 (26.7) 25 67 (43.3)
30 32 (38.3) 50 103 (81.9)
40 13 (43.0) 90 50 (100.0)
50 81 (72.2)
60 18 (78.7)
70 17 (84.8)
80 23 (93.1)
90 7 (95.7)
100 12 (100.0)
Hospitalisation during next 1 year
  
  
  
  
  
  
  
  
  
10 85 (29.6) 10 81 (31.1)
20 33 (41.1) 25 62 (47.8)
30 34 (53.0) 50 95 (79.6)
40 10 (56.4) 90 61 (100.0)
50 54 (75.3)
60 12 (79.4)
70 14 (84.2)
80 15 (89.5)
90 6 (91.6)
100 24 (100.0)
IBD- surgery during next 5 years
  
  
  
  
  
  
  
  
  
10 106 (37.2) 10 90 (38.1)
20 31 (48.1) 25 50 (50.2)
30 24 (56.5) 50 87 (79.3)
40 11 (60.4) 90 62 (100.0)
50 49 (77.5)
60 9 (80.7)
70 11 (84.6)
80 12 (88.8)
90 8 (91.6)
100 24 (100.0)
Colorectal cancer during next 20 years
  
  
  
  
  
  
  
  
  
10 124 (42.6) 10 110 (39.5)
20 31 (53.3) 25 50 (53.5)
30 32 (64.3) 50 84 (81.6)
40 9 (67.4) 90 55 (100.0)
50 47 (83.5)
60 8 (86.3)
70 3 (87.3)
80 13 (91.8)
90 4 (93.1)
100 20 (100.0)
patients’ acceptance of risk,27 may form the basis for 
developing an educational intervention. Medication 
adherence is consistently associated with the belief 
in the need for medication and low concerns about 
potential side effects.20 23 28 The key message for a treat 
to target intervention may therefore need to focus on 
highlighting the benefits of the approach, in order to 
demonstrate the need for treatment.19 29
Patient’s symptoms and objective control of inflam-
mation often do not match, and up to 25% of patients 
with symptoms have no objective inflammation, while 
another quarter are asymptomatic, yet have detectable 
mucosal inflammation.8 While some studies suggest 
that patients with occult inflammation are at increased 
risk of disease complication a recent study from our 
centre found no increased risk of flare in those with 
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occult inflammation.30 In our cohort we found a weak 
correlation with patient- reported disease state and FC 
for the current disease state. As we defined clinical 
remission as a period of 2 weeks prior to participation 
this likely reflects residual inflammation from recent 
flares.
The key strengths of our study are the large cohort of 
patients in clinical remission. For the cohort examined, 
treat to target is most relevant, as we only included 
patients in clinical remission. We deliberately chose 
conditions that reflect day- to- day practice, where treat 
to target would change treatment the most. A further 
strength is that the interviews were standardised and 
delivered by a single research nurse, thereby achieving 
consistency. There are, however, a number of limita-
tions. First, the study was conducted in a single centre, 
and therefore may have been influenced by the treat-
ment approach at this centre. Second, the study scenario 
was hypothetical, and therefore we can only make 
assumptions based on how the findings would trans-
late into real- world clinical practice when proposing 
concrete treatments. Third, in order not to overload 
the scenario further we did not ask about treatment 
risks such as infective complications or lymphoma 
that were studied in previous work.27 Fourth, again in 
order not to overload the scenario further and to keep 
the complexity of the scenario low we did not suggest 
any specific changes to medical treatment (injection vs 
infusions vs oral medication) or the measures required 
for future assessment of the treatment target (colonos-
copy vs calprotectin vs clinical outcomes). Fifth, we 
did not specifically ask patient why they gave their 
specific score on the acceptability of treat to target and 
can therefore not provide granular detail why patients 
chose not to accept the approach.
It is important to understand patient views on 
treat to target before attempting implementation. As 
we have demonstrated, 66% accept a treat to target 
approach, but a substantial minority do not. Patient 
education and counselling materials will therefore 
need to be developed to convince relevant patients of 
the importance of this strategy.
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